PYC Therapeutics to Participate in the Evercore ISI GenomeRx Emerging Therapeutic Company Day

NEW YORK and PERTH, Australia, May 26, 2021 /PRNewswire/ -- PYC Therapeutics (ASX: PYC), a biotechnology company developing a new generation of precision RNA therapeutics to change the lives of patients with inherited diseases, today announced it will participate as one of a select group of companies at the upcoming Evercore ISI GenomeRx Emerging Therapeutic Company Day, taking place virtually on June 3.

Members of PYC's management team will participate in one-on-one meetings with U.S. biotech and life science investors at the event.

About PYC Therapeutics

PYC Therapeutics (ASX: PYC) is a development-stage biotechnology company pioneering a new generation of RNA therapeutics that utilize PYC's proprietary library of naturally derived cell penetrating peptides to overcome the major challenges of current genetic medicines. PYC believes its PPMO (Peptide conjugated Phosphorodiamidate Morpholino Oligomer) technology enables a safer and more effective RNA therapeutic to address the underlying drivers of a range of genetic diseases for which no treatment solutions exist today. The Company is leveraging its leading-edge science to develop a pipeline of novel therapies including three preclinical stage programs focused on inherited eye diseases and a preclinical discovery program focused on neurodegenerative diseases. PYC's discovery and laboratory operations are located in Australia, and the Company recently launched an expansion into the U.S. for its preclinical, clinical, regulatory and business development operations. For more information, visit pyctx.com, or follow us on LinkedIn and Twitter.

Forward looking statements

Any forward-looking statements in this ASX announcement have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside the Company's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this ASX announcement include known and unknown risks. Because actual results could differ materially to assumptions made and the Company's current intentions, plans, expectations and beliefs about the future, you are urged to view all forward-looking statements contained in this ASX announcement with caution. The Company undertakes no obligation to publicly update any forward-looking statement whether as a result of new information, future events or otherwise.

CONTACTS:

INVESTORS

Deborah Elson/Matthew DeYoung

Argot Partners

deborah@argotpartners.com

matthew@argotpartners.com

MEDIA

Leo Vartorella

Argot Partners

leo@argotpartners.com

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/pyc-therapeutics-to-participate-in-the-evercore-isi-genomerx-emerging-therapeutic-company-day-301298908.html

SOURCE PYC Therapeutics


Company Codes: Australia:PYC

Back to news